Improvement of spinal inflammation in Ankylosing spondylitis (AS) by infliximab therapy as assessed by a magnetic resonance Imaging (MRI) using a novel evaluated spinal scoring system - Results of a double-blind placebo-controlled trial.

被引：0
|
作者：
Braun, J
Baraliakos, X
Golder, W
Listing, J
Brandt, J
Bollow, M
Sieper, J
van der Heijde, D
机构：
[1] Rheumazentrum Ruhrgebiet, Herne, Germany
[2] Free Univ Berlin, D-1000 Berlin, Germany
[3] Free Univ Herne, Herne, Germany
[4] Univ Hosp, Maastricht, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 2002年 / 46卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S426 / S427
页数：2
相关论文
共 50 条
  • [21] Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial
    Haibel, H.
    Fendler, C.
    Listing, J.
    Callhoff, J.
    Braun, J.
    Sieper, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 243 - 246
  • [22] Efficacy of Oral Prednisolone in Active Ankylosing Spondylitis: Results of a Double-Blind, Randomised, Placebo-Controlled Short-Term Trial
    Lunzer, R.
    JOURNAL FUR MINERALSTOFFWECHSEL, 2013, 20 (04): : 174 - 175
  • [23] Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial
    Feldman, SR
    Gordon, KB
    Bala, M
    Evans, R
    Li, S
    Dooley, LT
    Guzzo, C
    Patel, K
    Menter, A
    Gottlieb, AB
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (05) : 954 - 960
  • [24] Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
    Horneff, Gerd
    Fitter, Sigrid
    Foeldvari, Ivan
    Minden, Kirsten
    Kuemmerle-Deschner, Jasmin
    Tzaribacev, Nicolay
    Thon, Angelika
    Borte, Michael
    Ganser, Gerd
    Trauzeddel, Rolf
    Huppertz, Hans-Iko
    ARTHRITIS RESEARCH & THERAPY, 2012, 14 (05)
  • [25] Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
    Gerd Horneff
    Sigrid Fitter
    Ivan Foeldvari
    Kirsten Minden
    Jasmin Kuemmerle-Deschner
    Nicolay Tzaribacev
    Angelika Thon
    Michael Borte
    Gerd Ganser
    Rolf Trauzeddel
    Hans-Iko Huppertz
    Arthritis Research & Therapy, 14
  • [26] RAPID AND SUSTAINED IMPROVEMENT WITH TNFα BLOCKADE IN EARLY RA: RESULTS FROM A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING INFLIXIMAB WITH MRI OUTCOME
    Quinn, M. A.
    Conaghan, P. G.
    Greenstein, A.
    O'Connor, P.
    Karim, Z.
    Fraser, A.
    Brown, C.
    Jarret, S.
    Emery, P.
    RHEUMATOLOGY, 2003, 42 : 16 - 16
  • [27] TOCILIZUMAB (TCZ) IS NOT EFFECTIVE FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS (AS): RESULTS OF A PHASE 2, INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Sieper, J.
    Porter-Brown, B.
    Thompson, L.
    Harari, O.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 110 - 111
  • [28] Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
    van der Heijde, Desiree
    Baraliakos, Xenofon
    Sieper, Joachim
    Deodhar, Atul
    Inman, Robert D.
    Kameda, Hideto
    Zeng, Xiaofeng
    Sui, Yunxia
    Bu, Xianwei
    Pangan, Aileen L.
    Wung, Peter
    Song, In-Ho
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (11) : 1515 - 1523
  • [29] CANaDian evaluation of low DosE infliximab in Ankylosing spondylitis (CANDLE)-12 week magnetic resonance imaging evaluation of spinal inflammation with the SPARCC MRI method
    Maksymowych, Walter
    Salonen, David
    Inman, Robert
    Filipow, Paul
    Lambert, Robert
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1211 - 1212
  • [30] Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after two years of treatment with the anti-TNF agent infliximab
    Baraliakos, X
    Listing, J
    Brandt, J
    Rudwaleit, M
    Sieper, J
    Braun, J
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 323 - 323
12345